Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects

References

• Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229–37. doi:10.1056/NEJMoa2029849.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–51. doi:10.1056/NEJMoa2035002.
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–44. doi:10.1001/jama.2021.0202.
   PubMed Web of Science ®Google Scholar
• Keeler SP, Fox JM. Requirement of Fc-Fc gamma receptor interaction for antibody-based protection against emerging virus infections. Viruses. 2021:13. doi:10.3390/v13061037.
   PubMed Web of Science ®Google Scholar
• Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015;67(2):171–82. doi:10.1016/j.molimm.2015.03.255.
   PubMed Web of Science ®Google Scholar
• Ferrante A, Beard LJ, Feldman RG. IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J. 1990;9(8Suppl):S16–24. doi:10.1097/00006454-199008001-00004.
   PubMed Web of Science ®Google Scholar
• Wagner DK, Graham BS, Wright PF, Walsh EE, Kim HW, Reimer CB, Nelson DL, Chanock RM, Murphy BR. Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol. 1986;24(2):304–06. doi:10.1128/jcm.24.2.304-306.1986.
   PubMed Web of Science ®Google Scholar
• Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, De Haas M, et al. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential. Nat Commun. 2011;2(1):599. doi:10.1038/ncomms1608.
   PubMed Web of Science ®Google Scholar
• Pelegrin M, Naranjo-Gomez M, Piechaczyk M. Antiviral monoclonal antibodies: can they be more than simple neutralizing agents? Trends Microbiol. 2015;23(10):653–65. doi:10.1016/j.tim.2015.07.005.
   PubMed Web of Science ®Google Scholar
• Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody structure and function: the basis for Engineering Therapeutics. Antibodies (Basel). 2019:8. doi:10.3390/antib8040055.
   PubMedGoogle Scholar
• Wang P, Gajjar MR, Yu J, Padte NN, Gettie A, Blanchard JL, Russell-Lodrigue K, Liao LE, Perelson AS, Huang Y, et al. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti-HIV-1 IgG1 antibodies in vivo. Proc Natl Acad Sci USA. 2020;117(30):18002–09. doi:10.1073/pnas.2008190117.
   PubMed Web of Science ®Google Scholar
• van Erp EA, Luytjes W, Ferwerda G, van Kasteren PB. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10:548. doi:10.3389/fimmu.2019.00548.
   PubMed Web of Science ®Google Scholar
• Junker F, Gordon J, Qureshi O. Fc gamma receptors and their role in antigen uptake, presentation, and T cell activation. Front Immunol. 2020;11:1393. doi:10.3389/fimmu.2020.01393.
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, Fisher RI, Kelleher RJ, Bankert RB, Bernstein SH. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a “vaccinal effect” of rituximab. Blood. 2009;113(16):3809–12. doi:10.1182/blood-2008-10-185280.
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Ravetch JV. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell. 2015;161(5):1035–45. doi:10.1016/j.cell.2015.04.016.
   PubMed Web of Science ®Google Scholar
• Ahangarzadeh S, Payandeh Z, Arezumand R, Shahzamani K, Yarian F, Alibakhshi A. An update on antiviral antibody-based biopharmaceuticals. Int Immunopharmacol. 2020;86:106760. doi:10.1016/j.intimp.2020.106760.
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157(2):220–33. doi:10.1111/j.1476-5381.2009.00190.x.
   PubMed Web of Science ®Google Scholar
• Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS. 2009;4(5):388–93. doi:10.1097/COH.0b013e32832f0a89.
   PubMed Web of Science ®Google Scholar
• Jegaskanda S, Vanderven HA, Wheatley AK, Kent SJ. Fc or not Fc; that is the question: antibody Fc-receptor interactions are key to universal influenza vaccine design. Hum Vaccin Immunother. 2017;13(6):1–9. doi:10.1080/21645515.2017.1290018.
   PubMed Web of Science ®Google Scholar
• Yu X, Cragg MS. Engineered antibodies to combat viral threats. Nature. 2020;588(7838):398–99. doi:10.1038/d41586-020-03196-2.
   PubMed Web of Science ®Google Scholar
• IgG BS. Fc receptors: evolutionary considerations. Curr Top Microbiol Immunol. 2019;423:1–11. doi:10.1007/82_2019_149.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Corti D, Virgin HW, Ravetch JV. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature. 2020;588(7838):485–90. doi:10.1038/s41586-020-2838-z.
   PubMed Web of Science ®Google Scholar
• Gunn BM, Alter G. Modulating antibody functionality in infectious disease and vaccination. Trends Mol Med. 2016;22(11):969–82. doi:10.1016/j.molmed.2016.09.002.
   PubMed Web of Science ®Google Scholar
• Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol. 2002;2(9):706–13. doi:10.1038/nri891.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Ravetch JV. Diversification of IgG effector functions. Int Immunol. 2017;29(7):303–10. doi:10.1093/intimm/dxx025.
   PubMed Web of Science ®Google Scholar
• Yang C, Gao X, Gong R. Engineering of Fc fragments with optimized physicochemical properties implying improvement of clinical potentials for Fc-based therapeutics. Front Immunol. 2018;8:1860. doi:10.3389/fimmu.2017.01860.
   PubMed Web of Science ®Google Scholar
• Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296. doi:10.3389/fimmu.2019.01296.
   PubMed Web of Science ®Google Scholar
• Ducancel F, Muller BH. Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs. 2012;4(4):445–57. doi:10.4161/mabs.20776.
   PubMed Web of Science ®Google Scholar
• Garber K. Hunt for improved monoclonals against coronavirus gathers pace. Nat Biotechnol. 2021;39(1):9–12. doi:10.1038/s41587-020-00791-6.
   PubMed Web of Science ®Google Scholar
• Morris AB, Farley CR, Pinelli DF, Adams LE, Cragg MS, Boss JM, Scharer CD, Fribourg M, Cravedi P, Heeger PS, et al. Signaling through the Inhibitory Fc receptor FcγRIIB induces CD8+ T cell apoptosis to limit T cell immunity. Immunity. 2020;52(1):136–150.e6. doi:10.1016/j.immuni.2019.12.006.
   PubMed Web of Science ®Google Scholar
• Chauhan AK, Chen C, Moore TL, DiPaolo RJ. Induced expression of FcγRIIIa (CD16a) on CD4+ T cells triggers generation of IFN-γhigh subset. J Biol Chem. 2015;290(8):5127–40. doi:10.1074/jbc.M114.599266.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20(10):633–43. doi:10.1038/s41577-020-00410-0.
   PubMed Web of Science ®Google Scholar
• De Taeye SW, Rispens T, Vidarsson G. The ligands for human IgG and their effector functions. Antibodies (Basel). 2019:8. doi:10.3390/antib8020030.
   PubMedGoogle Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:10.3389/fimmu.2014.00520.
   PubMed Web of Science ®Google Scholar
• Ben Mkaddem S, Benhamou M, Monteiro RC. Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools. Front Immunol. 2019;10:811. doi:10.3389/fimmu.2019.00811.
   PubMed Web of Science ®Google Scholar
• Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN. The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol. 2014;14(2):94–108. doi:10.1038/nri3582.
   PubMed Web of Science ®Google Scholar
• Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol. 2014;192(5):2252–60. doi:10.4049/jimmunol.1301249.
   PubMed Web of Science ®Google Scholar
• Tay MZ, Wiehe K, Pollara J. Antibody-dependent cellular phagocytosis in antiviral immune responses. Front Immunol. 2019;10:332. doi:10.3389/fimmu.2019.00332.
   PubMed Web of Science ®Google Scholar
• Araki N, Hatae T, Furukawa A, Swanson JA. Phosphoinositide-3-kinase-independent contractile activities associated with Fcγ-receptor-mediated phagocytosis and macropinocytosis in macrophages. J Cell Sci. 2003;116(2):247–57. doi:10.1242/jcs.00235.
   PubMed Web of Science ®Google Scholar
• Huang Z-Y, Barreda DR, Worth RG, Indik ZK, Kim M-K, Chien P, Schreiber AD. Differential kinase requirements in human and mouse Fc-gamma receptor phagocytosis and endocytosis. J Leukoc Biol. 2006;80(6):1553–62. doi:10.1189/jlb.0106019.
   PubMed Web of Science ®Google Scholar
• Mantegazza AR, Magalhaes JG, Amigorena S, Marks MS. Presentation of phagocytosed antigens by MHC class I and II. Traffic. 2013;14(2):135–52. doi:10.1111/tra.12026.
   PubMed Web of Science ®Google Scholar
• Parcina M, Wendt C, Goetz F, Zawatzky R, Zähringer U, Heeg K, Bekeredjian-Ding I. Staphylococcus aureus-induced plasmacytoid dendritic cell activation is based on an IgG-mediated memory response. J Immunol. 2008;181(6):3823–33. doi:10.4049/jimmunol.181.6.3823.
   PubMed Web of Science ®Google Scholar
• Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O’Garra A, Vicari A, Trinchieri TG. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med. 2005;201(7):1157–67. doi:10.1084/jem.20041930.
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck J-P, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19(2):225–34. doi:10.1016/s1074-7613(03)00208-5.
   PubMed Web of Science ®Google Scholar
• Worley MJ, Fei K, Lopez-Denman AJ, Kelleher AD, Kent SJ, Chung AW. Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. J Immunol Methods. 2018;457:41–52. doi:10.1016/j.jim.2018.03.007.
   PubMed Web of Science ®Google Scholar
• Gao R, Sheng Z, Sreenivasan CC, Wang D, Influenza LF. A virus antibodies with antibody-dependent cellular cytotoxicity function. Viruses. 2020:12. doi:10.3390/v12030276.
   PubMed Web of Science ®Google Scholar
• Salk HM, Haralambieva IH, Ovsyannikova IG, Goergen KM, Poland GA. Granzyme B ELISPOT assay to measure influenza-specific cellular immunity. J Immunol Methods. 2013;398-399:44–50. doi:10.1016/j.jim.2013.09.007.
   PubMed Web of Science ®Google Scholar
• Borsos T, Rapp HJ. Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte. J Immunol. 1965;95:559–66.
   PubMedGoogle Scholar
• Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343(6176):1260–63. doi:10.1126/science.1248943.
   PubMed Web of Science ®Google Scholar
• Kellner C, Derer S, Valerius T, Peipp PM. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods. 2014;65(1):105–13. doi:10.1016/j.ymeth.2013.06.036.
   PubMed Web of Science ®Google Scholar
• Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc–FcγR interactions in IgG-mediated microbial neutralization. J Exp Med. 2015;212(9):1361–69. doi:10.1084/jem.20151267.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Ravetch JV. Fcγ receptor function and the design of vaccination strategies. Immunity. 2017;47(2):224–33. doi:10.1016/j.immuni.2017.07.009.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Ravetch JV. Fcγ receptor pathways during active and passive immunization. Immunol Rev. 2015;268(1):88–103. doi:10.1111/imr.12343.
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Eko FO, He Q, Black CM. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev Vaccines. 2004;3(1):23–34. doi:10.1586/14760584.3.1.23.
   PubMedGoogle Scholar
• Regnault A, Lankar D, Lacabanne V, Rodriguez A, Théry C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, et al. Fcγ receptor–mediated induction of dendritic cell maturation and major histocompatibility complex class i–restricted antigen presentation after immune complex internalization. J Exp Med. 1999;189(2):371–80. doi:10.1084/jem.189.2.371.
   PubMed Web of Science ®Google Scholar
• Munroe ME, Bishop GA. A costimulatory function for T cell CD40. J Immunol. 2007;178(2):671–82. doi:10.4049/jimmunol.178.2.671.
   PubMed Web of Science ®Google Scholar
• Chan KR, Ong EZ, Mok DZ, Ooi EE. Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases. Expert Rev Anti-Infect Ther. 2015;13(11):1351–60. doi:10.1586/14787210.2015.1079127.
   PubMed Web of Science ®Google Scholar
• Lev A, Sigal L. Getting in front and behind the enemy lines to counter virus infection. Cell Host Microbe. 2013;13(2):121–22. doi:10.1016/j.chom.2013.01.013.
   PubMed Web of Science ®Google Scholar
• den Dunnen J, Vogelpoel LT, Wypych T, Muller FJ, De Boer L, Kuijpers TW, Zaat SA, Kapsenberg ML, de Jong EC. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and FcγRIIa in human dendritic cells. Blood. 2012;120(1):112–21. doi:10.1182/blood-2011-12-399931.
   PubMed Web of Science ®Google Scholar
• Boonnak K, Dambach KM, Donofrio GC, Tassaneetrithep B, Marovich MA. Cell type specificity and host genetic polymorphisms influence antibody-dependent enhancement of dengue virus infection. J Virol. 2011;85(4):1671–83. doi:10.1128/JVI.00220-10.
   PubMed Web of Science ®Google Scholar
• Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA. 2010;107(46):19985–90. doi:10.1073/pnas.1014074107.
   PubMed Web of Science ®Google Scholar
• Foss S, Watkinson RE, Grevys A, McAdam MB, Bern M, Høydahl LS, Dalhus B, Michaelsen TE, Sandlie I, James LC, et al. TRIM21 immune signaling is more sensitive to antibody affinity than its neutralization activity. J Immunol. 2016;196(8):3452–59. doi:10.4049/jimmunol.1502601.
   PubMed Web of Science ®Google Scholar
• McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013;14(4):327–36. doi:10.1038/ni.2548.
   PubMed Web of Science ®Google Scholar
• Clift D, So C, McEwan WA, James LC, Schuh SM. Publisher Correction: acute and rapid degradation of endogenous proteins by Trim-Away. Nat Protoc. 2019;14(8):2596. doi:10.1038/s41596-018-0092-8.
   PubMed Web of Science ®Google Scholar
• Caddy SL, Vaysburd M, Papa G, Wing M, O’Connell K, Stoycheva D, Foss S, Terje Andersen J, Oxenius A, James LC. Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity. EMBO J. 2021;40(5):e106228. doi:10.15252/embj.2020106228.
   PubMed Web of Science ®Google Scholar
• Hangartner L, Zinkernagel RM, Hengartner H. Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol. 2006;6(3):231–43. doi:10.1038/nri1783.
   PubMed Web of Science ®Google Scholar
• Mackness BC, Jaworski JA, Boudanova E, Park A, Valente D, Mauriac C, Pasquier O, Schmidt T, Kabiri M, Kandira A, et al. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. MAbs. 2019;11(7):1276–88. doi:10.1080/19420862.2019.1633883.
   PubMed Web of Science ®Google Scholar
• Bai Y, Ye L, Tesar DB, Song H, Zhao D, Björkman PJ, Roopenian DC, Zhu X. Intracellular neutralization of viral infection in polarized epithelial cells by neonatal Fc receptor (FcRn)-mediated IgG transport. Proc Natl Acad Sci USA. 2011;108(45):18406–11. doi:10.1073/pnas.1115348108.
   PubMed Web of Science ®Google Scholar
• Baker K, Rath T, Pyzik M, Blumberg RS. The role of FcRn in antigen presentation. Front Immunol. 2014;5:408. doi:10.3389/fimmu.2014.00408.
   PubMed Web of Science ®Google Scholar
• Ward ES, Devanaboyina SC, Ober RJ. Targeting FcRn for the modulation of antibody dynamics. Mol Immunol. 2015;67(2):131–41. doi:10.1016/j.molimm.2015.02.007.
   PubMed Web of Science ®Google Scholar
• Qiao S-W, Kobayashi K, Johansen F-E, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS. Dependence of antibody-mediated presentation of antigen on FcRn. Proc Natl Acad Sci USA. 2008;105(27):9337–42. doi:10.1073/pnas.0801717105.
   PubMed Web of Science ®Google Scholar
• Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, Zlobec I, Karamitopoulou E, Stachler MD, Odze RD, et al. Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer. Immunity. 2013;39(6):1095–107. doi:10.1016/j.immuni.2013.11.003.
   PubMed Web of Science ®Google Scholar
• Rath T, Baker K, Pyzik M, Blumberg RS. Regulation of immune responses by the neonatal Fc receptor and its therapeutic implications. Front Immunol. 2014;5:664. doi:10.3389/fimmu.2014.00664.
   PubMed Web of Science ®Google Scholar
• Richardson SI, Moore PL. Targeting Fc effector function in vaccine design. Expert Opin Ther Targets. 2021;25(6):467–77. doi:10.1080/14728222.2021.1907343.
   PubMed Web of Science ®Google Scholar
• Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, Halkerston R, Hill J, Jenkin D, Stockdale L, et al. Author Correction: phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27(6):1113. doi:10.1038/s41591-021-01372-z.
   PubMed Web of Science ®Google Scholar
• Chaudhury S, Ockenhouse CF, Regules JA, Dutta S, Wallqvist A, Jongert E, Waters NC, Lemiale F, Bergmann-Leitner E. The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity. Malar J. 2016;15(1):301. doi:10.1186/s12936-016-1348-9.
   PubMed Web of Science ®Google Scholar
• Kurtovic L, Atre T, Feng G, Wines BD, Chan J-A, Boyle MJ, Drew DR, Hogarth PM, Fowkes FJI, Bergmann-Leitner ES, et al. Multifunctional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase 1/2a trial. J Infect Dis. 2020. doi:10.1093/infdis/jiaa144.
   PubMed Web of Science ®Google Scholar
• Coler RN, Day TA, Ellis R, Piazza FM, Beckmann AM, Vergara J, Rolf T, Lu L, Alter G, Hokey D, et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. Npj Vaccines. 2018;3(1):34. doi:10.1038/s41541-018-0057-5.
   PubMed Web of Science ®Google Scholar
• Bournazos S, DiLillo DJ, Goff AJ, Glass PJ, Ravetch JV. Differential requirements for FcγR engagement by protective antibodies against Ebola virus. Proc Natl Acad Sci USA. 2019;116(40):20054–62. doi:10.1073/pnas.1911842116.
   PubMed Web of Science ®Google Scholar
• Chan CEZ, Seah SGK, Chye H, Massey S, Torres M, Lim APC, Wong SKK, Neo JJY, Wong PS, Lim JH, et al. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLOS ONE. 2021;16(6):e0253487. doi:10.1371/journal.pone.0253487.
   PubMed Web of Science ®Google Scholar
• Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussières G, Brassard N, Laumaea A, Vézina D, Prévost J, et al. A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe. 2021;29(7):1137–1150.e6. doi:10.1016/j.chom.2021.06.001.
   PubMed Web of Science ®Google Scholar
• Suscovich TJ, Fallon JK, Das J, Demas AR, Crain J, Linde CH, Michell A, Natarajan H, Arevalo C, Broge T, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. Sci Transl Med. 2020;12(553):eabb4757. doi:10.1126/scitranslmed.abb4757.
   PubMed Web of Science ®Google Scholar
• Nelson CS, Huffman T, Jenks JA, Cisneros de la Rosa E, Xie G, Vandergrift N, Pass RF, Pollara J, Permar SR. HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl Acad Sci USA. 2018;115(24):6267–72. doi:10.1073/pnas.1800177115.
   PubMed Web of Science ®Google Scholar
• Perez LG, Martinez DR, deCamp AC, Pinter A, Berman PW, Francis D, Sinangil F, Lee C, Greene K, Gao H, et al. V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. PLOS ONE. 2017;12(7):e0180720. doi:10.1371/journal.pone.0180720.
   PubMed Web of Science ®Google Scholar
• Excler J-L, Ake J, Robb ML, Kim JH, Plotkin SA, Papasian CJ. Nonneutralizing functional antibodies: a new “old” paradigm for HIV vaccines. Clin Vaccine Immunol. 2014;21(8):1023–36. doi:10.1128/CVI.00230-14.
   PubMed Web of Science ®Google Scholar
• Tomaras GD, Plotkin SA. Complex immune correlates of protection in HIV-1 vaccine efficacy trials. Immunol Rev. 2017;275(1):245–61. doi:10.1111/imr.12514.
   PubMed Web of Science ®Google Scholar
• Sondermann P, Szymkowski DE. Harnessing Fc receptor biology in the design of therapeutic antibodies. Curr Opin Immunol. 2016;40:78–87. doi:10.1016/j.coi.2016.03.005.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9(1):63–73. doi:10.1007/s13238-017-0473-8.
   PubMed Web of Science ®Google Scholar
• Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Johnson S, Bonvini E, Koenig S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res. 2007;67(18):8882–90. doi:10.1158/0008-5472.CAN-07-0696.
   PubMed Web of Science ®Google Scholar
• Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):R123. doi:10.1186/bcr3069.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Ann Oncol. 2017;28(4):855–61. doi:10.1093/annonc/mdx002.
   PubMed Web of Science ®Google Scholar
• Mimoto F, Katada H, Kadono S, Igawa T, Kuramochi T, Muraoka M, Wada Y, Haraya K, Miyazaki T, Hattori K. Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131. Protein Eng Des Sel. 2013;26(10):589–98. doi:10.1093/protein/gzt022.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Pegram MD, Musolino A, Bachelot T, Wright GS, De Laurentiis M, et al. Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. Cancer Res. 2020;80:Abstract nr GS1–02.
   Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem. 2001;276(9):6591–604. doi:10.1074/jbc.M009483200.
   PubMed Web of Science ®Google Scholar
• Irvine EB, Alter G. Understanding the role of antibody glycosylation through the lens of severe viral and bacterial diseases. Glycobiology. 2020;30(4):241–53. doi:10.1093/glycob/cwaa018.
   PubMed Web of Science ®Google Scholar
• Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25(1):21–50. doi:10.1146/annurev.immunol.25.022106.141702.
   PubMed Web of Science ®Google Scholar
• Walker MR, Lund J, Thompson KM, Jefferis R. Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing FcγRI and/or FcγRII receptors. Biochem J. 1989;259(2):347–53. doi:10.1042/bj2590347.
   PubMed Web of Science ®Google Scholar
• Jefferis R. Glycosylation of antibody therapeutics: optimisation for purpose. Methods Mol Biol. 2009;483:223–38. doi:10.1007/978-1-59745-407-0_13.
   PubMedGoogle Scholar
• Umaña P, Jean–Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999;17(2):176–80. doi:10.1038/6179.
   PubMed Web of Science ®Google Scholar
• Ferrara C, Grau S, Jäger C, Sondermann P, Brünker P, Waldhauer I, Hennig M, Ruf A, Rufer AC, Stihle M, et al. Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA. 2011;108(31):12669–74. doi:10.1073/pnas.1108455108.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733–40. doi:10.1074/jbc.M202069200.
   PubMed Web of Science ®Google Scholar
• Ito A, Ishida T, Yano H, Inagaki A, Suzuki S, Sato F, Takino H, Mori F, Ri M, Kusumoto S, et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother. 2009;58(8):1195–206. doi:10.1007/s00262-008-0632-0.
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs. 2012;4(4):419–25. doi:10.4161/mabs.20996.
   PubMed Web of Science ®Google Scholar
• Evans JB, Syed BA. From the analyst’s couch: next-generation antibodies. Nat Rev Drug Discov. 2014;13(6):413–14. doi:10.1038/nrd4255.
   PubMed Web of Science ®Google Scholar
• Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-engineering for modulated effector functions-improving antibodies for cancer treatment. Antibodies (Basel). 2020:9. doi:10.3390/antib9040064.
   PubMedGoogle Scholar
• Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci USA. 2014;111(16):5992–97. doi:10.1073/pnas.1402458111.
   PubMed Web of Science ®Google Scholar
• Ackerman ME, Moldt B, Wyatt RT, Dugast A-S, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366(1–2):8–19. doi:10.1016/j.jim.2010.12.016.
   PubMed Web of Science ®Google Scholar
• Boesch AW, Miles AR, Chan YN, Osei-Owusu NY, Ackerman ME. IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs. MAbs. 2017;9(3):455–65. doi:10.1080/19420862.2016.1274845.
   PubMed Web of Science ®Google Scholar
• Jung ST, Kelton W, Kang TH, Ng DT, Andersen JT, Sandlie I, Sarkar CA, Georgiou G. Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity. ACS Chem Biol. 2013;8(2):368–75. doi:10.1021/cb300455f.
   PubMed Web of Science ®Google Scholar
• Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. 2008;7(8):2517–27. doi:10.1158/1535-7163.MCT-08-0201.
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA. 2006;103(11):4005–10. doi:10.1073/pnas.0508123103.
   PubMed Web of Science ®Google Scholar
• Smith P, DiLillo DJ, Bournazos S, Li F, Ravetch JV. Mouse model recapitulating human Fcgamma receptor structural and functional diversity. Proc Natl Acad Sci USA. 2012;109(16):6181–86. doi:10.1073/pnas.1203954109.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Keremane SR, Vielmetter J, Bjorkman PJ. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa. J Struct Biol. 2016;194(1):78–89. doi:10.1016/j.jsb.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Introna M, Golay J. Complement in antibody therapy: friend or foe? Blood. 2009;114(26):5247–48. doi:10.1182/blood-2009-10-249532.
   PubMed Web of Science ®Google Scholar
• Lee CH, Romain G, Yan W, Watanabe M, Charab W, Todorova B, Lee J, Triplett K, Donkor M, Lungu OI, et al. Correction: corrigendum: IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions. Nat Immunol. 2017;18:1173. doi:10.1038/ni1017-1173c.
   Web of Science ®Google Scholar
• Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs. 2010;2(2):181–89. doi:10.4161/mabs.2.2.11158.
   PubMed Web of Science ®Google Scholar
• Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, Ultsch M, Mulkerrin MG. Engineered antibodies with increased activity to recruit complement. J Immunol. 2001;166(4):2571–75. doi:10.4049/jimmunol.166.4.2571.
   PubMed Web of Science ®Google Scholar
• de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, Wang G, et al. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLOS Biol. 2016;14(1):e1002344. doi:10.1371/journal.pbio.1002344.
   PubMed Web of Science ®Google Scholar
• Schütze K, Petry K, Hambach J, Schuster N, Fumey W, Schriewer L, Röckendorf J, Menzel S, Albrecht B, Haag F, et al. CD38-specific biparatopic heavy chain antibodies display potent complement-dependent cytotoxicity against multiple myeloma cells. Front Immunol. 2018;9:2553. doi:10.3389/fimmu.2018.02553.
   PubMed Web of Science ®Google Scholar
• Ravetch JV, Bournazos S Human IgG Fc domain variants with improved effector function. United States patent WO/2019/125846. 2019 June 27.
   Google Scholar
• Weitzenfeld P, Bournazos S, Ravetch JV. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. J Clin Invest. 2019;129(9):3952–62. doi:10.1172/JCI128437.
   PubMed Web of Science ®Google Scholar
• Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, Kamikawa T, Shida-Kawazoe M, Hattori K. Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant. MAbs. 2013;5(2):229–36. doi:10.4161/mabs.23452.
   PubMed Web of Science ®Google Scholar
• Wang G, de Jong RN, van den Bremer EJ, Beurskens FJ, Labrijn AF, Ugurlar D, Gros P, Schuurman J, Parren PHI, Heck AR. Molecular basis of assembly and activation of complement component C1 in complex with immunoglobulin G1 and antigen. Mol Cell. 2016;63(1):135–45. doi:10.1016/j.molcel.2016.05.016.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514–24. doi:10.1074/jbc.M604292200.
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IW, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–59. doi:10.1038/nbt.1601.
   PubMed Web of Science ®Google Scholar
• Ko S, Jo M, Jung ST. Recent achievements and challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc engineering. BioDrugs. 2021;35(2):147–57. doi:10.1007/s40259-021-00471-0.
   PubMed Web of Science ®Google Scholar
• Foss S, Watkinson R, Sandlie I, James LC, Andersen JT. TRIM 21: a cytosolic Fc receptor with broad antibody isotype specificity. Immunol Rev. 2015;268(1):328–39. doi:10.1111/imr.12363.
   PubMed Web of Science ®Google Scholar
• Ng PML, Kaliaperumal N, Lee CY, Chin WJ, Tan HC, Au VB, Goh AX, Tan QW, Yeo DSG, Connolly JE, et al. Enhancing antigen cross-presentation in human monocyte-derived dendritic cells by recruiting the intracellular Fc receptor TRIM21. J Immunol. 2019;202(8):2307–19. doi:10.4049/jimmunol.1800462.
   PubMed Web of Science ®Google Scholar
• Foss S, Bottermann M, Jonsson A, Sandlie I, James LC, Andersen JT. TRIM21—from intracellular immunity to therapy. Front Immunol. 2019;10:2049. doi:10.3389/fimmu.2019.02049.
   PubMed Web of Science ®Google Scholar
• Tam JC, Bidgood SR, McEwan WA, James LC. Intracellular sensing of complement C3 activates cell autonomous immunity. Science. 2014;345(6201):1256070. doi:10.1126/science.1256070.
   PubMed Web of Science ®Google Scholar
• Bottermann M, Foss S, Caddy SL, Clift D, van Tienen LM, Vaysburd M, Cruickshank J, O’Connell K, Clark J, Mayes K, et al. Complement C4 prevents viral infection through capsid inactivation. Cell Host Microbe. 2019;25(4):617–629.e7. doi:10.1016/j.chom.2019.02.016.
   PubMed Web of Science ®Google Scholar
• Clift D, McEwan WA, Labzin LI, Konieczny V, Mogessie B, James LC, Schuh M. A method for the acute and rapid degradation of endogenous proteins. Cell. 2017;171(7):1692–1706.e18. doi:10.1016/j.cell.2017.10.033.
   PubMed Web of Science ®Google Scholar
• Zeng J, Santos AF, Mukadam AS, Osswald M, Jacques DA, Dickson CF, McLaughlin SH, Johnson CM, Kiss L, Luptak J, et al. Target-induced clustering activates Trim-Away of pathogens and proteins. Nat Struct Mol Biol. 2021;28(3):278–89. doi:10.1038/s41594-021-00560-2.
   PubMed Web of Science ®Google Scholar
• Gautam R, Nishimura Y, Gaughan N, Gazumyan A, Schoofs T, Buckler-White A, Seaman MS, Swihart BJ, Follmann DA, Nussenzweig MC, et al. A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection. Nat Med. 2018;24(5):610–16. doi:10.1038/s41591-018-0001-2.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. 2002;169(9):5171–80. doi:10.4049/jimmunol.169.9.5171.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall’acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–53. doi:10.1128/AAC.01285-13.
   PubMed Web of Science ®Google Scholar
• Dolgin E. ‘Super-antibodies’ could curb COVID-19 and help avert future pandemics. Nat Biotechnol. 2021;39(7):783–85. doi:10.1038/s41587-021-00980-x.
   PubMed Web of Science ®Google Scholar
• Corti D, Purcell LA, Snell G, Veesler VD. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell. 2021;184(12):3086–108. doi:10.1016/j.cell.2021.05.005.
   PubMed Web of Science ®Google Scholar
• YG-R AG, Juarez E, Casal MC, Moya J, Falci DR, Sarkis E, Solis J, Hanzhe Z, Scott N, Cathcart AL, et al., for the COMET-ICE Investigators. Early Covid-19 treatment with SARS-CoV-2 neutralizing antibody Sotrovimab. medRxiv. 2021. doi:10.1101/2021.05.27.21257096.
   Google Scholar
• Dimitrov DS. Engineered CH2 domains (nanoantibodies). MAbs. 2009;1(1):26–28. doi:10.4161/mabs.1.1.7480.
   PubMed Web of Science ®Google Scholar
• Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res. 2020;9:72. doi:10.12688/f1000research.22211.2.
   PubMedGoogle Scholar
• Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel. 2010;23(4):289–97. doi:10.1093/protein/gzq005.
   PubMed Web of Science ®Google Scholar
• Traxlmayr MW, Faer M, Stadlmayr G, Hasenhindl C, Antes B, Rüker F, Obinger C. Directed evolution of stabilized IgG1-Fc scaffolds by application of strong heat shock to libraries displayed on yeast. Biochim Biophys Acta. 2012;1824(4):542–49. doi:10.1016/j.bbapap.2012.01.006.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou Z, Zhu S-L, Zu X, Wang Z, Zhang L-K, Wang W, Xiao G. A novel RSV F-Fc fusion protein vaccine reduces lung injury induced by respiratory syncytial virus infection. Antiviral Res. 2019;165:11–22. doi:10.1016/j.antiviral.2019.02.017.
   PubMed Web of Science ®Google Scholar
• Divine R, Dang HV, Ueda G, Fallas JA, Vulovic I, Sheffler W, Saini S, Zhao YT, Raj IX, Morawski PA, et al. Designed proteins assemble antibodies into modular nanocages. bioRxiv. 2020. doi:10.1101/2020.12.01.406611.
   Google Scholar
• Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced Fc RIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol. 2012;86(11):6189–96. doi:10.1128/JVI.00491-12.
   PubMed Web of Science ®Google Scholar
• Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. J Biochem. 2006;140(3):359–68. doi:10.1093/jb/mvj157.
   PubMed Web of Science ®Google Scholar
• Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, Hiatt A, Ngo L, Steinkellner H, Whaley KJ, et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc Natl Acad Sci USA. 2011;108(51):20690–94. doi:10.1073/pnas.1108360108.
   PubMed Web of Science ®Google Scholar
• Lu L, Palaniyandi S, Zeng R, Bai Y, Liu X, Wang Y, Pauza CD, Roopenian DC, Zhu X. A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol. 2011;85(20):10542–53. doi:10.1128/JVI.05441-11.
   PubMed Web of Science ®Google Scholar
• Jaworski JP, Kobie J, Brower Z, Malherbe DC, Landucci G, Sutton WF, Guo B, Reed JS, Leon EJ, Engelmann F, et al. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIV SF162P3-infected infant rhesus macaques. J Virol. 2013;87(19):10447–59. doi:10.1128/JVI.00049-13.
   PubMed Web of Science ®Google Scholar
• Euler Z, Alter G. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication. AIDS Res Hum Retroviruses. 2015;31(1):13–24. doi:10.1089/aid.2014.0235.
   PubMed Web of Science ®Google Scholar
• Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid M, Agostini ML, Guarino B, Di Iulio J, Rosen L, Tucker H, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021. doi:10.1101/2021.03.09.434607.
   Google Scholar
• Ullah I, Prévost J, Ladinsky MS, Stone H, Lu M, Anand SP, Beaudoin-Bussières G, Symmes K, Benlarbi M, Ding S, et al. Live imaging of SARS-CoV-2 infection in mice reveals neutralizing antibodies require Fc function for optimal efficacy. bioRxiv. 2021. doi:10.1101/2021.03.22.436337.
   Google Scholar
• Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, Zost SJ, Jang H, Huang Y, Allen JD, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell. 2021;184(7):1804–1820.e16. doi:10.1016/j.cell.2021.02.026.
   PubMed Web of Science ®Google Scholar
• Liu Z, Xu W, Xia S, Gu C, Wang X, Wang Q, Zhou J, Wu Y, Cai X, Qu D, et al. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020;5(1):282. doi:10.1038/s41392-020-00402-5.
   PubMed Web of Science ®Google Scholar
• He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006;176(10):6085–92. doi:10.4049/jimmunol.176.10.6085.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47. doi:10.1038/nri2206.
   PubMed Web of Science ®Google Scholar
• Du L, Zhao G, Chan CC, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng B-J, et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009;393(1):144–50. doi:10.1016/j.virol.2009.07.018.
   PubMed Web of Science ®Google Scholar
• Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Zost SJ, Jang H, Huang Y, Allen JD, Case JB, et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection. bioRxiv. 2020. doi:10.1101/2020.12.28.424554.
   Google Scholar
• Chenoweth AM, Wines BD, Anania JC, Mark Hogarth P. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs. Immunol Cell Biol. 2020;98(4):287–304. doi:10.1111/imcb.12326.
   PubMed Web of Science ®Google Scholar
• Asokan M, Dias J, Liu C, Maximova A, Ernste K, Pegu A, McKee K, Shi W, Chen X, Almasri C, et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc Natl Acad Sci USA. 2020;117(31):18754–63. doi:10.1073/pnas.2008236117.
   PubMed Web of Science ®Google Scholar
• Goulet DR, Atkins WM. Considerations for the design of Antibody-Based Therapeutics. J Pharm Sci. 2020;109:74–103. doi:10.1016/j.xphs.2019.05.031.
   PubMed Web of Science ®Google Scholar
• Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat Biotechnol. 2020;38(7):789–91. doi:10.1038/s41587-020-0577-1.
   PubMed Web of Science ®Google Scholar
• Ramadhany R, Hirai I, Sasaki T, Ono K, Ramasoota P, Ikuta K, Kurosu T. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection. Antiviral Res. 2015;124:61–68. doi:10.1016/j.antiviral.2015.10.012.
   PubMed Web of Science ®Google Scholar
• Correia IR. Stability of IgG isotypes in serum. MAbs. 2010;2(3):221–32. doi:10.4161/mabs.2.3.11788.
   PubMed Web of Science ®Google Scholar
• Muhammed Y. The best IgG subclass for the development of therapeutic monoclonal antibody drugs and their commercial production: a review. Immunome Res. 2020;16:173. doi:10.35248/1745-7580.20.16.173.
   Google Scholar
• Aalberse RC, IgG4 SJ. breaking the rules. Immunology. 2002;105(1):9–19. doi:10.1046/j.0019-2805.2001.01341.x.
   PubMed Web of Science ®Google Scholar
• Wang S, Peng Y, Wang R, Jiao S, Wang M, Huang W, Shan C, Jiang W, Li Z, Gu C, et al. Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys. Nat Commun. 2020;11(1):5752. doi:10.1038/s41467-020-19568-1.
   PubMed Web of Science ®Google Scholar